Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Use of Acetyl Salicylic Acid and Terbutalin in Assisted Reproductive Techniques (ART)

This study has been completed.
Information provided by:
Sykehuset Telemark Identifier:
First received: August 17, 2007
Last updated: July 20, 2011
Last verified: July 2011
This study aims to determine the possible effects of Acetyl Salicylic Acid (ASA) and Terbutalin on ART treatment.

Condition Intervention
Reproductive Techniques, Assisted
Drug: Acetyl Salicylic Acid and Terbutalin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Use of Acetylsalicylic Acid and Terbutalin in ART

Resource links provided by NLM:

Further study details as provided by Sykehuset Telemark:

Primary Outcome Measures:
  • Pregnancy [ Time Frame: 7 weeks ] [ Designated as safety issue: No ]

Enrollment: 300
Study Start Date: March 2006
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Acetyl Salicylic Acid and Terbutalin
ASA 75 mg, Terbutalin 5mg
No Intervention: 2
Experimental: 3
Drug: Acetyl Salicylic Acid and Terbutalin
ASA 75 mg, Terbutalin 5mg
No Intervention: 4
Experimental: 5
Drug: Acetyl Salicylic Acid and Terbutalin
ASA 75 mg, Terbutalin 5mg
No Intervention: 6

Detailed Description:
This study aims to determine the possible effects of ASA and Terbutalin on ART treatment.

Ages Eligible for Study:   18 Years to 39 Years   (Adult)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Infertile women below 39 years of age

Exclusion Criteria:

  • Women who may react allergically to the drugs administered
  • Women with hyperthyroid or IDDM
  • Women who do not want to participate in the study
  • Women who are unable to give informed, written consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00518141

STHF, Kvinneklinikken, Fertilitetsklinikken Sor
Porsgrunn, Telemark, Norway, 3901
Sponsors and Collaborators
Sykehuset Telemark
Principal Investigator: Jarl A Kahn, Dr. med STHF, Kvinneklinikken, Fertilitetsklinikken Sor
  More Information

Responsible Party: Jarl Kahn, Fertilitetsklinikken Sør Identifier: NCT00518141     History of Changes
Other Study ID Numbers: S-06085 (REK) 
Study First Received: August 17, 2007
Last Updated: July 20, 2011
Health Authority: Norway:National Committee for Medical and Health Research Ethics

Additional relevant MeSH terms:
Salicylic Acid
Anti-Infective Agents
Antifungal Agents
Keratolytic Agents
Dermatologic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Fibrinolytic Agents
Fibrin Modulating Agents
Platelet Aggregation Inhibitors
Antipyretics processed this record on January 14, 2017